Compare Adaptive Biotechnologies Corp (ADPT) vs Global X Defense Tech ETF (SHLD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Global X Defense Tech ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.13 (market cap $3.33B), while Global X Defense Tech ETF trades at $62.47. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | SHLD | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Sector/Thematic |
52-Week High | $22.37 | $78.02 |
52-Week Low | $10.24 | $58.20 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
SHLD (Global X Defense Tech ETF) trades at $64.84, up 1.38% with a bullish technical signal supported by moving averages and ADX indicators. The defense sector benefits from global military spending growth, with recent UK defense overhaul and Pentagon AI investments driving positive sentiment. The ETF provides diversified exposure to defense technology companies amid accelerating global rearmament trends.
The outlook remains positive given structural defense spending increases, though competition from other defense ETFs and valuation concerns present risks. Technical indicators suggest potential resistance near $65-66 levels, while sector momentum supports continued investor interest in defense technology exposure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →
